Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
INSYS Therapeutics Inc
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00956254CT.gov Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mucositis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fentanyl Sublingual Spray (this asset) | INSYS Therapeutics Inc | P3 | BB · 64 |
| Palifermin | Barbara Ann Karmanos Cancer Institute | P3 | BB |
| Calcium Phosphate | Children's Oncology Group | P3 | BB |
| Folic Acid | Niels Fristrup | P2 | CCC |
| tk-112690 | Tosk, Inc. | P2 | CCC |
| Everolimus | Emory University | P2 | CCC |
| Pteroylmonoglutamic Acid Hydrolase G2 | University College, London | P1/2 | CCC |
| Methotrexate | University College, London | P1/2 | CCC |
| Melphalan | Sherif S. Farag | P1 | CC |
+1 more in the Mucositis cohort
Other indications for Fentanyl Sublingual Spray
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P3 | B · 62 |
| Cancer | — | P3 | CCC · 54 |
| Chronic Pain Syndrome | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fentanyl Sublingual Spray in Mucositis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fentanyl-sublingual-spray-mucositis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →